Histone Deacetylases (HDAC) Inhibitor—Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor

Histone Deacetylases (HDAC) Inhibitor—Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor

The inhibition of histone deacetylases (HDACs) holds promise as a potential anti-cancer therapy as histone and non-histone protein acetylation is frequently disrupted in cancer, leading to cancer initiation and progression. Additionally, the use of a histone deacetylase inhibitor (HDACi) such as the...

Full description

Bibliographic Details
Main Authors: Małgorzata Drzewiecka, Anna Gajos-Michniewicz, Grażyna Hoser, Dominika Jaśniak, Gabriela Barszczewska-Pietraszek, Przemysław Sitarek, Piotr Czarny, Janusz Piekarski, Maciej Radek, Małgorzata Czyż, Tomasz Skorski, Tomasz Śliwiński
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Genes
Subjects:
melanoma
HDACi
PARP1
valproic acid
alkylating agent
DNA damage
Online Access:https://www.mdpi.com/2073-4425/14/6/1295

Internet

https://www.mdpi.com/2073-4425/14/6/1295

Similar Items